Investor Presentation

November 2020

Disclaimer

This presentation has been prepared by Genetic Signatures Limited ("GSS"). The information contained in this presentation is for information purposes only and has been prepared for use in conjunction with a verbal presentation and should be read in that context. This presentation is proprietary to GSS. It may not be reproduced, disseminated, quoted or referred to, in whole or in part, without the express consent of GSS.

The information contained in this presentation is not investment or financial product advice and is not intended to be used as the basis for making an investment decision. Please note that, in providing this presentation, GSS has not considered the objectives, financial position or needs of any particular recipient. GSS strongly suggests that investors consult a financial advisor prior to making an investment decision.

No representation or warranty, express or implied, is made as to the fairness, accuracy, completeness or correctness of the information, opinions and conclusions contained in this presentation. To the maximum extent permitted by law, none of GSS, its related bodies corporate, shareholders or respective directors, officers, employees, agents or advisors, nor any other person accepts any liability, including, without limitation, any liability arising out of fault or negligence for any loss arising from the use of information contained in this presentation.

This presentation includes "forward looking statements" within the meaning of securities laws of applicable jurisdictions. Forward looking statements can generally be identified by the use of the words "anticipate", "believe", "expect", "project", "forecast", "estimate", "likely", "intend", "should", "could", "may", "target", "plan" "guidance" and other similar expressions. Such forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties and other factors, many of which are beyond the control of GSS and its officers, employees, agents or associates, that may cause actual results to differ materially from those expressed or implied in such statement. Actual results, performance or achievements may vary materially from any projections and forward-looking statements and the assumptions on which those statements are based. Readers are cautioned not to place undue reliance on forward looking statements and GSS assumes no obligation to update such information.

This presentation is not, and does not constitute, an offer to sell or the solicitation, invitation or recommendation to purchase, any securities and neither this presentation nor anything contained in it forms the basis of any contract or commitment. Without limiting this, this presentation does not constitute an offer to sell, or a solicitation of an offer to buy, any securities in the United States. The securities of GSS have not been, and will not be, registered under the U.S. Securities Act of 1933, as amended (Securities Act) or the securities laws of any state or other jurisdiction of the United States, and may not be offered or sold in the United States except in compliance with the registration requirements of the Securities Act and any other applicable securities laws or pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and any other applicable securities laws.

GSS Snapshot

Genetic Signatures *EasyScreen*™ Kits

Enteric
Detects 20+ gastroenteritis pathogens including Salmonella, Giardia and Norovirus)

Respiratory
Detects 14 common respiratory infections including Influenza types A&B, Rhinovirus and SARS-CoV-2)

ESBL & CPO
Detection of antibiotic resistant pathogens also colloquially known as "superbugs"

STI / Genital
Detects the most prevalent pathogen infections (Chlamydia, Gonorrhoeae, Syphilis and Trichomoniasis) plus many others

Flavivirus / Alphavirus
Refers to mosquito born pathogens including Dengue fever, Zika virus,West Nile virus and others

Meningitis
Detects 8 viral meningitis pathogens, a life-threatening infection surrounding the brain and spinal cord

Respiratory Atypical
Additional targets under the Respiratory banner

Revenue from operations (A$m)



Asia Pacific Update

- FY20 revenue **increased 116% to $10.2m** (FY19: $4.7m) and includes instrument sales of $0.7m
- Received TGA registration and **launched *EasyScreen*™ SARS-CoV-2 Detection kit** across Australia
- Underpinned by **strong demand for *EasyScreen*™ SARS-CoV-2 Detection Kit** – which is currently being used both as a standalone test and in combination with the broader ***EasyScreen*™ Respiratory Pathogen Detection Kit by new and existing customers**
- Significantly **increased production capacity** to meet current demand and **more production expansion underway**
- Application lodged with **TGA for *EasyScreen*™ STI / Genital Pathogen Detection Kit**
- Work is set to recommence on the *EasyScreen*™ Flavivirus / Alphavirus Detection Kit **to support a future TGA registration**

Genetic Signatures

EMEA Update

- **Europe is a key focus** through FY21 and beyond
- **Additional sales and support staff appointed** to support growing pipeline of opportunities
- Direct presence in **UK, Netherlands and Germany** and distributors in **Greece, Ireland, Italy, Spain, Benelux** and **Poland**
- **Achieved European registration** (CE-IVD) for the *EasyScreen*™ SARS-CoV-2 Detection Kit and product launched
- FY20 revenue **increased 580% to $1.1m,** (FY19: $0.2m), including instrument sales of $0.3m, representing 10% of total FY20 revenue (FY19: 3%) – and grew to 15% in 1Q FY21
- **New customers established**, including three new European distributors – **strategically partnering** with customers interested in the broad range of *EasyScreen*™ Detection Kits
- European applications for *EasyScreen*™ STI / Genital Pathogen Detection Kit lodged

Genetic Signatures

North America Update

- **Largest market opportunity globally**, representing an estimated **42%** of the global molecular testing market[1]
- Pursuing a **direct sales approach** with **approved laboratories**
- **Expanded sales team appointed** with strong pedigree in the industry
- **Legally able to sell *EasyScreen*™ SARS-CoV-2 Detection Kit** to US laboratories certified to perform high complexity testing. The FDA allows sales under a EUA Section **IVc exemption**[2]
- Initial **clinical trials have commenced** for FDA clearance of the ***EasyScreen*™ Enteric Protozoan Detection Kit** FDA, despite disruptions caused by COVID-19
- **Canadian distributor** appointed – Somagen Diagnostic, Inc
- **New warehouse facility** established and stocked in Los Angeles

Genetic Signatures

1. Global market size (A$m per annum) - Kalorama Information, Molecular Testing Markets for Infectious Diseases (Sepsis, Respiratory Diseases, HIV, Hepatitis, TB Testing, STIs and Other Tests), July 2019, and company estimates; 2. The FDA is permitting manufacturers that have or will submit an EUA for a SARS-CoV-2 test to supply their test prior to receiving the EUA. The FDA describes this marketing route in Section IV.C. of their Policy for Coronavirus Disease-2019 Tests During the Public Health Emergency (Revised)2 Under the exemption the manufacturer must have validated the kit and is required to notify the FDA of their intent to supply the test. The use of the test is limited to laboratories that have been certified under CLIA (Clinical Laboratory Improvement Amendments) to perform high complexity testing and the laboratory is required to disclaim the status of the test on all results that are issued using the test. (https://www.fda.gov/regulatory-information/search-fda-guidance-documents/policy-coronavirus-disease-2019-tests-during-public-health-emergency-revised)

Looking Forward

Multiple growth opportunities to be pursued in tandem, creating significant upside potential

Focus on long-term customer contracts and customer satisfaction

- Focus on securing long-term customer contracts with high throughput pathology groups, hospitals or government run programs
- Provide reliable and quality customer service to strong customer relationships
- Favourable unit economics expected to underpin growth through FY21 and beyond

Leverage COVID-19 momentum and promote new tests to exisiting customers

- Increasing international recognition through the *EasyScreen™* SARS-CoV-2 launch creates new avenues to expand the customer base
- Tests become embedded in workflow and customers typically adopt new tests once workflow established leading to favourable unit economics
- Targeting first North American contracts

Development of new *EasyScreen™ Kits*

- FDA submission for the *EasyScreen*™ Enteric Protozoan Detection Kit
- CE-IVD and TGA registration for *EasyScreen*™ STI / Genital Pathogen Detection Kits
- CE-IVD and TGA registration for *EasyScreen*™ Flavivirus / Alphavirus Detection Kits
- Continued development of other new kits

Genetic Signatures

Genetic Signatures

Contact us

Dr John Melki

Genetic Signatures

Chief Executive Officer

P: +61 (0)2 9870 7580

E: john.melki@geneticsignatures.com

Visit us

www.geneticsignatures.com

Follow us on social media